Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript - Thomson StreetEvents

Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript

Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript - Thomson StreetEvents
Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript
Published Oct 16, 2023
49 pages (36805 words) — Published Oct 16, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of RARE.OQ corporate analyst meeting

  
Brief Excerpt:

...Good morning, everyone. We're going to get started. It's great to see all of you here at the St. Regis and those of you online, beautiful day in New York City to be together and do a traditional Analyst Day. We haven't done one for a while that we're an important inflection point for the company with so much going on. We thought it was an opportunity to really get you updated on all the pieces of what's happening with the company, which is what we'll do today. So on your sheet, you'll see an agenda on the table there. And we'll basically -- I'll be starting with some opening remarks. We'll do a deep dive into UX143 for OI, a deep dive then into Angelman syndrome. And after a break, then we'll do a deep dive into our gene therapy franchise, including the Wilson and some initial data on Wilson for all of you. So...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Ultragenyx Pharmaceutical Inc
Ticker
RARE.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Priyanka Arun Grover - JPMorgan Chase & Co, Research Division - Analyst : Yes. This is Priyanka Grover on for Anupam Rama of JPMorgan. You had previously mentioned when answering the first question that there is a 20% of fracture reduction rate with bisphosphonates, though the literature is a little all over the place on this. How confident are you on this assumption as it relates to putting setrusumab fracture rate data into context?

Question: Priyanka Arun Grover - JPMorgan Chase & Co, Research Division - Analyst : Priyanka again for Anupam Rama at JPMorgan. I just had a scientific question regarding the PPCA beta amyloid interaction. Is there more color on the MOA in the sense that is it increasing phagocytosis within the cells to lead to the intake of the beta-amyloid? And is it almost, I would say, like

Table Of Contents

Ultragenyx Pharmaceutical Inc at TD Cowen Health Care Conference Transcript – 2024-03-04 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 4-Mar-24 2:10pm GMT

Ultragenyx Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript – 2023-11-14 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 14-Nov-23 12:30pm GMT

Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Summary – 2023-11-02 – US$ 54.00 – Preliminary Brief of RARE.OQ earnings conference call or presentation 2-Nov-23 9:00pm GMT

Ultragenyx Pharmaceutical Inc Q3 2023 Earnings Call Transcript – 2023-11-02 – US$ 54.00 – Edited Transcript of RARE.OQ earnings conference call or presentation 2-Nov-23 9:00pm GMT

Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Summary – 2023-10-16 – US$ 54.00 – Edited Brief of RARE.OQ corporate analyst meeting</ 16-Oct-23 12:30pm GMT

Ultragenyx Pharmaceutical Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-12 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 12-Sep-23 12:50pm GMT

Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference Summary – 2023-09-06 – US$ 54.00 – Edited Brief of RARE.OQ presentation 6-Sep-23 12:50pm GMT

Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference Transcript – 2023-09-06 – US$ 54.00 – Edited Transcript of RARE.OQ presentation 6-Sep-23 12:50pm GMT

Ultragenyx Pharmaceutical Inc Q2 2023 Earnings Call Summary – 2023-08-03 – US$ 54.00 – Edited Brief of RARE.OQ earnings conference call or presentation 3-Aug-23 9:00pm GMT

Ultragenyx Pharmaceutical Inc Q2 2023 Earnings Call Transcript – 2023-08-03 – US$ 54.00 – Edited Transcript of RARE.OQ earnings conference call or presentation 3-Aug-23 9:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript" Oct 16, 2023. Alacra Store. May 03, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Ultragenyx-Pharmaceutical-Inc-Present-Pipeline-Update-at-Analyst-Day-T15765325>
  
APA:
Thomson StreetEvents. (2023). Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript Oct 16, 2023. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Ultragenyx-Pharmaceutical-Inc-Present-Pipeline-Update-at-Analyst-Day-T15765325>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.